Effectiveness of darbepoetin-alfa in combination with intravenous iron sucrose in patients with inflammatory bowel disease and refractory anaemia: A pilot study

European Journal of Gastroenterology and Hepatology

Volumn 18, Issue 4, 2006, Pages 421-425

  Koutroubakis, Ioannis E ^a   Karmiris, Konstantinos ^a   Makreas, Sokratis ^a   Xidakis, Costas ^a   Niniraki, Maria ^a   Kouroumalis, Elias A ^a  

^a UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Anaemia; Crohn's disease; Darbepoetin; Erythropoietin; Ulcerative colitis

Indexed keywords

AZATHIOPRINE; C REACTIVE PROTEIN; CORTICOSTEROID; ERYTHROPOIETIN; FERRIC HYDROXIDE SUCROSE; FERRITIN; HEMOGLOBIN; INFLIXIMAB; INTERLEUKIN 6; MESALAZINE; METHOTREXATE; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; SALAZOSULFAPYRIDINE; TRANSFERRIN; TRANSFERRIN RECEPTOR;

CLINICAL ARTICLE; CLINICAL OBSERVATION; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROHN DISEASE; DRUG DETERMINATION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FERRITIN BLOOD LEVEL; HEMATOPOIESIS; HUMAN; MALE; MEAN CORPUSCULAR VOLUME; PILOT STUDY; PRIORITY JOURNAL; RASH; REFRACTORY ANEMIA; SOLUBILITY; TRANSFERRIN BLOOD LEVEL; ULCERATIVE COLITIS;

ANEMIA, REFRACTORY; C-REACTIVE PROTEIN; DRUG THERAPY, COMBINATION; ERYTHROPOIETIN; FEMALE; FERRIC COMPOUNDS; FERRITINS; HEMATINICS; HEMOGLOBINS; HUMANS; INFLAMMATORY BOWEL DISEASES; INJECTIONS, INTRAVENOUS; INTERLEUKIN-6; MALE; PILOT PROJECTS; RECEPTORS, TRANSFERRIN; TRANSFERRIN; TREATMENT OUTCOME;

EID: 33645103364     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00042737-200604000-00017     Document Type: Conference Paper

References (23)

1. Gasche C, Lomer MC, Cavill I, Weiss G. Iron, anaemia, and inflammatory bowel diseases. Gut 2004; 53:1190-1197.
2. Wilson A, Reyes E, Ofman J. Prevalence and outcomes of anemia in inflammatory bowel disease: a systematic review of the literature. Am J Med 2004; 116 (suppl 7A):44S-49S.
3. Gasche C, Waldhoer T, Feichtenschlager T, Male C, Mayer A, Mittermaier C, Petritsch W. Prediction of response to iron sucrose in inflammatory bowel disease-associated anemia. Am J Gastroenterol 2001; 96:2382-2387.
4. Bodemar G, Kechagias S, Almer S, Danielson BG. Treatment of anemia in inflammatory bowel disease with iron sucrose. Scand J Gastroenterol 2004; 39:454-458.
5. Horina JH, Petritsch W, Schmid CR, Reicht G, Wenzl H, Silly H, Krejs GJ. Treatment of anemia in inflammatory bowel disease with recombinant human erythropoietin: results in three patients. Gastroenterology 1993; 104:1828-1831.
6. Schreiber S, Howaldt S, Schnoor M, Nikolaus S, Bauditz J, Gasche C, et al. Recombinant erythropoietin for the treatment of anemia in inflammatory bowel disease. N Engl J Med 1996; 334:619-623.
7. Gasche C, Dejaco C, Waldhoer T, Tillinger W, Reinisch W, Fueger GF, et al. Intravenous iron and erythropoietin for anemia associated with Crohn's disease. A randomised, controlled trial. Ann Intern Med 1997; 126:782-787.
8. Dohil R, Hassall E, Wadsworth LD, Israel DM. Recombinant human erythropoietin for treatment of anemia of chronic disease in children with Crohn's disease. J Pediatr 1998; 132:155-159.
9. Christodoulou DK, Tsianos EV. Anaemia in inflammatory bowel disease - the role of recombinant human erythropoietin. Eur J Intern Med 2000; 11:222-227.
10. Egrie JC, Dwyer E, Browne JK, Hitz A, Lykos MA. Darbepoetin alfa has a longer circulating half-life and greater in vivo potency than recombinant human erythropoietin. Exp Hematol 2003; 31:290-299.
11. Egrie JC, Browne JK. Development and characterisation of novel erythropoiesis stimulating protein (NESP). Br J Cancer 2001; 84 (suppl 1):3-10.
12. Cournoyer D, Toffelmire EB, Wells GA, Barber DL, Barrett BJ, Delage R, et al. Anti-erythropoietin antibody-mediated pure red cell aplasia after treatment with recombinant erythropoietin products: recommendations for minimization of risk. J Am Soc Nephrol 2004; 15:2728-2734.
13. Casadevall N. Pure red cell aplasia and anti-erythropoietin antibodies in patients treated with epoetin. Nephrol Dial Transplant 2003; 189 (suppl 8):37-41.
14. Toto RD, Pichette V, Navarro J, Brenner R, Carroll W, Liu W, Roger S. Darbepoetin alfa effectively treats anemia in patients with chronic kidney disease with de novo every-other-week administration. Am J Nephrol 2004; 24:453-460.
15. Macdougall IC, Matcham J, Gray SJ. Correction of anemia with darbepoetin alfa in patients with chronic kidney disease receiving dialysis. Nephrol Dial Transplant 2003; 18:576-581.
16. Hesketh RJ, Arena F, Patel D, Austin M, D'Avirro P, Rossi G, et al. A randomized controlled trial of darbepoetin alfa administered as a fixed or weight-based dose using a front-loading schedule in patients with anemia who have non-myeloid malignancies. Cancer 2004; 100:859-868.
17. Smith RE Jr, Tchekmedyian NS, Chan D, Meza LA, Northfelt DW, Patel R, et al. A dose- and schedule-finding study of darbepoetin alfa for the treatment of chronic anaemia of cancer. Br J Cancer 2003; 88:1851-1858.
18. Coccia MA, Cooke K, Stoney G, Pistillo J, Del Castillo J, Duryea D, et al. Novel erythropoiesis stimulating protein (darbepoetin alfa) alleviates anemia associated with chronic inflammatory disease in a rodent model. Exp Hematol 2001; 29:1201-1209.
19. Lennard-Jones JE. Classification of inflammatory bowel disease. Scand J Gastroenterol 1989; 24 (suppl):2-6.
20. Best WR, Becktel JM, Singleton JW, Kern F Jr. Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. Gastroenterology 1976; 70:439-444.
21. Walmsley RS, Ayres RC, Pounder RE, Allan RN. A simple clinical colitis activity index. Gut 1998; 43:29-32.
22. Pujade-Lauraine E, Topham C. Once-weekly treatment of anemia in patients with cancer: a comparative review of epoetins. Oncology 2005; 68:122-129.
23. Gasche C, Reinisch W, Lochs H, Parsaei B, Bakos S, Wyatt J, et al. Anemia in Crohn's disease. Importance of inadequate erythropoietin production and iron deficiency. Dig Dis Sci 1994; 39:1930-1934.